Heterologous prime-boost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 6, 2007, Pages 672-685

  Pasetti, M F ^a   Resendiz Albor, A ^a   Ramirez, K ^a   Stout, R ^b   Papania, M ^c   Adams, R J ^d   Polack, F P ^d   Ward, B J ^e   Burt, D ^f   Chabot, S ^e   Ulmer, J ^g   Barry, E M ^a   Levine, M M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Bioject Inc   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f GLAXOSMITHKLINE   (United States)

^g Novartis Vaccines and Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MATERNAL ANTIBODY; MEASLES VACCINE; PROTEASOME; SHIGELLA VACCINE; VIRUS FUSION PROTEIN; VIRUS HEMAGGLUTININ;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEVICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; IMMUNIZATION; IMMUNOGENICITY; MEASLES; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; REPLICON; RHESUS MONKEY; SINDBIS VIRUS; TREATMENT RESPONSE; VIREMIA;

AEROSOLS; ANIMALS; HEMAGGLUTININS, VIRAL; IMMUNIZATION; IMMUNIZATION, SECONDARY; INJECTIONS, INTRADERMAL; MACACA MULATTA; MEASLES; MEASLES VACCINE; MEASLES VIRUS; REPLICON; SINDBIS VIRUS; VACCINES, ATTENUATED; VACCINES, DNA;

EID: 36148931379     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100420     Document Type: Article

References (50)

1. Wolfson, L.J., Strebel, P.M., Gacic-Dobo, M., Hoekstra, E.J., McFarland, J.W. & Hersh, B.S. Measles initiative. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369, 191-200 (2007).
2. Tapia, M.D. et al. A serosurvey to identify the window of vulnerability to wild-type measles among infants in rural Mali. Am. J. Trop. Med. Hyg. 73, 26-31 (2005).
3. Stein, C.E., Birmingham, M., Kurian, M., Duclos, P. & Strebel, P. The global burden of measles in the year 2000 - a model that uses country-specific indicators. J. Infect. Dis. 187 (Suppl 1), S8-S14 (2003).
4. Pasetti, M.F. et al. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J. Virol. 77, 5209-5217 (2003).
5. Song, M.K. et al. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J. Virol. 79, 9854-9861 (2005).
6. Polo, J.M. et al. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev. Biol. (Basel) 104, 181-185 (2000).
7. Leitner, W.W. et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9, 33-39 (2003).
8. Cella, M. et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189, 821-829 (1999).
9. Kirman, J.R. et al. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect. Immun. 71, 575-579 (2003).
10. Leitner, W.W. et al. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22, 1537-1544 (2004).
11. Adkins, B., Leclerc, C. & Marshall-Clarke, S. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4, 553-564 (2004).
12. Stittelaar, K.J. et al. Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination. Vaccine 20, 2022-2026 (2002).
13. Polack, F.P. et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med. 6, 776-781 (2000).
14. Premenko-Lanier, M., Rota, P.A., Rhodes, G.H., Bellini, W.J. & McChesney, M.B. Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J. Infect. Dis. 189, 2064-2071 (2004).
15. Kotloff, K.L. et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J. Infect. Dis. 190, 1745-1754 (2004).
16. de Swart, R.L. et al. Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine 24, 6424-6436 (2006).
17. Chabot, S. et al. A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23, 1374-1383 (2005).
18. Moss, W.J., Ota, M.O. & Griffin, D.E. Measles: immune suppression and immune responses. Int. J. Biochem. Cell Biol. 36, 1380-1385 (2004).
19. Smith, A.W., Casey, H.W., LaCroix, J.T. & Johnson, D.K. Acute bloat syndrome (gastric dilatation) in Macaca mulatta. J. Am. Vet. Med. Assoc. 155, 1241-1244 (1969).
20. Polack, F.P. et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5, 629-634 (1999).
21. Polack, F.P., Hoffman, S.J., Crujeiras, G. & Griffin, D.E. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9, 1209-1213 (2003).
22. Cutts, F.T., Grabowsky, M. & Markowitz, L.E. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 23, 95-106 (1995).
23. Aaby, P. et al. Sex-specific differences in mortality after high-titre measles immunization in rural Senegal. Bull. World Health Organ. 72, 761-770 (1994).
24. Holt, E.A., Moulton, L.H., Siberry, G.K. & Halsey, N.A. Differential mortality by measles vaccine titer and sex. J. Infect. Dis. 168, 1087-1096 (1993).
25. Woodland, D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25, 98-104 (2004).
26. Kane, A., Lloyd, J., Zaffran, M., Simonsen, L. & Kane, M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull. World Health Organ. 77, 801-807 (1999).
27. Valdespino-Gomez, J.L. et al. Measles aerosol vaccination. Curr. Top. Microbiol. Immunol. 304, 165-193 (2006).
28. Treanor, J. et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24, 254-262 (2006).
29. Langley, J.M. et al. Safety and immunogenicity of a proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 24, 1601-1608 (2006).
30. Chen, R.T. et al. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162, 1036-1042 (1990).
31. Cutts, F.T. Module7: Measles, The Immunological Basis for Immunization Series (World health Organization, Geneva, 1993).
32. Ward, B.J. et al. Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test. Diagn. Microbiol. Infect. Dis. 33, 147-152 (1999).
33. Auwaerter, P.G. et al. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J. Infect. Dis. 180, 950-958 (1999).
34. El Mubarak, H.S. et al. Infection of cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type measles viruses. J. Gen. Virol. 88, 2028-2034 (2007).
35. Permar, S.R. et al. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J. Infect. Dis. 190, 998-1005 (2004).
36. van Binnendijk, R.S., van der Heijden, R.W., van, A.G., Uytdehaag, F.G. & Osterhaus, A.D. Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J. Infect. Dis. 170, 443-448 (1994).
37. van Binnendijk, R.S., van der Heijden, R.W. & Osterhaus, A.D. Monkeys in measles research. Curr. Top. Microbiol. Immunol. 191, 135-148 (1995).
38. Premenko-Lanier, M. et al. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology 307, 67-75 (2003).
39. Premenko-Lanier, M., Rota, P., Rhodes, G., Bellini, W. & McChesney, M. Prior DNA vaccination does not interfere with the live-attenuated measles vaccine. Vaccine 22, 762-765 (2004).
40. Pan, C.H. et al. Inaugural article: modulation of disease T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc. Natl. Acad. Sci. USA 102, 11581-11588 (2005).
41. Skiadopoulos, M.H., Surman, S.R., Riggs, J.M., Collins, P.L. & Murphy, B.R. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J. Virol. 75, 10498-10504 (2001).
42. Zhu, Y. et al. Evaluation of recombinant vaccinia virus - measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276, 202-213 (2000).
43. Stittelaar, K.J. et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74, 4236-4243 (2000).
44. Polack, F.P. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr. Res. 62, 111-115 (2007).
45. Merz, D.C., Scheid, A. & Choppin, P.W. Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J. Exp. Med. 151, 275-288 (1980).
46. Polack, F.P., Hoffman, S.J., Moss, W.J. & Griffin, D.E. Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J. Infect. Dis. 187, 1794-1800 (2003).
47. Kobune, F., Sakata, H. & Sugiura, A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J. Virol. 64, 700-705 (1990).
48. Capozzo, A.V. et al. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J. Immunol. 176, 5671-5681 (2006).
49. Tapia, M.D. et al. Measurement of tetanus antitoxin in oral fluid: a tool to conduct serosurveys 24. Pediatr. Infect. Dis. J. 25, 819-825 (2006).
50. de Souza, V.A., Pannuti, C.S., Sumita, L.M. & Andrade Junior, H.F. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J. Med. Virol. 52, 275-279 (1997).